Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials
The DOI matches its Crossref record.
Abstract
BACKGROUND: The T-20 Versus Optimized Background Regimen Only (TORO) 1 and TORO 2 clinical trials are open-label, controlled, parallel-group, phase 3 studies comparing enfuvirtide plus an optimized background (OB) of antiretrovirals (n = 661) with OB alone (n = 334) in treatment-experienced HIV-1-infected patients. METHODS: The primary objective at week 48 was to investigate durability of efficacy, as measured by the percentage of patients maintaining their week 24 response or improving. Efficacy analyses used the intent-to-treat population. RESULTS: A total of 73.7% of patients randomized to the enfuvirtide group remained on treatment through week 48 versus 21.3% originally randomized to the control group. At week 48, a higher proportion of week 24 responders maintained their response or were new responders in the enfuvirtide group than in the control group in each responder category: HIV-1 RNA level > or =1.0 log(10) change from baseline, <400 copies/mL and <50 copies/mL (37.4%, 30.4%, and 18.3% in the enfuvirtide group vs. 17.1%, 12.0%, and 7.8% in the control group, respectively; P < 0.0001 for all comparisons). CD4 cell count increases from baseline were twice as great in the enfuvirtide group as in the control group. CONCLUSION: These data demonstrate durable efficacy of enfuvirtide plus OB over 48 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Self-citationMaraviroc for Previously Treated Patients with R5 HIV-1 Infection
Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803152 · Cited by 752
Self-citationHIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications
Tang, M. W., & Shafer, R. W. (2012) · Drugs · doi:10.2165/11633630-000000000-00000 · Cited by 326
Paltiel, A. D., Freedberg, K. A., Scott, C. A., Schackman, B. R., Losina, E., Wang, B., Seage III, G. R., Sloan, C. E., Sax, P. E., & Walensky, R. P. (2009) · Clinical Infectious Diseases · doi:10.1086/597095 · Cited by 259
Losina, E., Schackman, B. R., Sadownik, S. N., Gebo, K. A., Walensky, R. P., Chiosi, J. J., Weinstein, M. C., Hicks, P. L., Aaronson, W. H., Moore, R. D., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/644772 · Cited by 180
Metadata
- Authors
- Nelson, M., Arastéh, K., Clotet, B., Cooper, D. A., Henry, K., Katlama, C., Lalezari, J. P., Lazzarin, A., Montaner, J. S. G., O'Hearn, M., Piliero, P. J., Reynes, J., Trottier, B., Walmsley, S. L., Cohen, C., Eron, J. J., Kuritzkes, D. R., Lange, J., Stellbrink, H.-J., Delfraissy, J.-F., Buss, N. E., Donatacci, L., Wat, C., Smiley, L., Wilkinson, M., Valentine, A., Guimaraes, D., DeMasi, R., Chung, J., & Salgo, M. P.
- Venue
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2005-12-01
- Volume
- 40
- Issue
- 4
- Pages
- 404-412
- ISSN
- 1525-4135 (ISSN-L)
- OpenAlex
- W2312642584
- Cited by
- 153
- References
- 0
- FWCI
- 13.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials. https://app.cochat.ai/papers/10.1097/01.qai.0000185314.56556.c3
- The paper
- Nelson, M., Arastéh, K., Clotet, B., Cooper, D. A., Henry, K., Katlama, C., Lalezari, J. P., Lazzarin, A., Montaner, J. S. G., O'Hearn, M., Piliero, P. J., Reynes, J., Trottier, B., Walmsley, S. L., Cohen, C., Eron, J. J., Kuritzkes, D. R., Lange, J., Stellbrink, H.-J., . . . Salgo, M. P. (2005). Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/01.qai.0000185314.56556.c3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.